Epinephrine HFA-MDI (E004) + Placebo-HFA

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Oct 1, 2012 โ†’ Dec 1, 2013

About Epinephrine HFA-MDI (E004) + Placebo-HFA

Epinephrine HFA-MDI (E004) + Placebo-HFA is a phase 3 stage product being developed by Amphastar Pharmaceuticals for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01737905. Target conditions include Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01737905Phase 3Completed